BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 23361914)

  • 1. [(3)H]UR-PLN196: a selective nonpeptide radioligand and insurmountable antagonist for the neuropeptide Y Y(2) receptor.
    Pluym N; Baumeister P; Keller M; Bernhardt G; Buschauer A
    ChemMedChem; 2013 Apr; 8(4):587-93. PubMed ID: 23361914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dimeric argininamide-type neuropeptide Y receptor antagonists: chiral discrimination between Y1 and Y4 receptors.
    Keller M; Kaske M; Holzammer T; Bernhardt G; Buschauer A
    Bioorg Med Chem; 2013 Nov; 21(21):6303-22. PubMed ID: 24074877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [³H]UR-MK136: a highly potent and selective radioligand for neuropeptide Y Y₁ receptors.
    Keller M; Bernhardt G; Buschauer A
    ChemMedChem; 2011 Sep; 6(9):1566-71. PubMed ID: 21732539
    [No Abstract]   [Full Text] [Related]  

  • 4. Guanidine-acylguanidine bioisosteric approach in the design of radioligands: synthesis of a tritium-labeled N(G)-propionylargininamide ([3H]-UR-MK114) as a highly potent and selective neuropeptide Y Y1 receptor antagonist.
    Keller M; Pop N; Hutzler C; Beck-Sickinger AG; Bernhardt G; Buschauer A
    J Med Chem; 2008 Dec; 51(24):8168-72. PubMed ID: 19053784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Red-fluorescent argininamide-type NPY Y1 receptor antagonists as pharmacological tools.
    Keller M; Erdmann D; Pop N; Pluym N; Teng S; Bernhardt G; Buschauer A
    Bioorg Med Chem; 2011 May; 19(9):2859-78. PubMed ID: 21493077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bivalent argininamide-type neuropeptide y y(1) antagonists do not support the hypothesis of receptor dimerisation.
    Keller M; Teng S; Bernhardt G; Buschauer A
    ChemMedChem; 2009 Oct; 4(10):1733-45. PubMed ID: 19672917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modular synthesis of non-peptidic bivalent NPY Y1 receptor antagonists.
    Weiss S; Keller M; Bernhardt G; Buschauer A; König B
    Bioorg Med Chem; 2008 Nov; 16(22):9858-66. PubMed ID: 18851917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N(ω)-Carbamoylation of the Argininamide Moiety: An Avenue to Insurmountable NPY Y1 Receptor Antagonists and a Radiolabeled Selective High-Affinity Molecular Tool ([(3)H]UR-MK299) with Extended Residence Time.
    Keller M; Weiss S; Hutzler C; Kuhn KK; Mollereau C; Dukorn S; Schindler L; Bernhardt G; König B; Buschauer A
    J Med Chem; 2015 Nov; 58(22):8834-49. PubMed ID: 26466164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward Labeled Argininamide-Type NPY Y1 Receptor Antagonists: Identification of a Favorable Propionylation Site in BIBO3304.
    Keller M; Schindler L; Bernhardt G; Buschauer A
    Arch Pharm (Weinheim); 2015 Jun; 348(6):390-8. PubMed ID: 25884646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor.
    Sautel M; Rudolf K; Wittneben H; Herzog H; Martinez R; Munoz M; Eberlein W; Engel W; Walker P; Beck-Sickinger AG
    Mol Pharmacol; 1996 Aug; 50(2):285-92. PubMed ID: 8700135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and characterization of the first fluorescent nonpeptide NPY Y1 receptor antagonist.
    Schneider E; Keller M; Brennauer A; Hoefelschweiger BK; Gross D; Wolfbeis OS; Bernhardt G; Buschauer A
    Chembiochem; 2007 Nov; 8(16):1981-8. PubMed ID: 17876753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of the guanidine-acylguanidine bioisosteric approach to argininamide-type NPY Y₂ receptor antagonists.
    Pluym N; Brennauer A; Keller M; Ziemek R; Pop N; Bernhardt G; Buschauer A
    ChemMedChem; 2011 Sep; 6(9):1727-38. PubMed ID: 21692185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorescence- and luminescence-based methods for the determination of affinity and activity of neuropeptide Y2 receptor ligands.
    Ziemek R; Brennauer A; Schneider E; Cabrele C; Beck-Sickinger AG; Bernhardt G; Buschauer A
    Eur J Pharmacol; 2006 Dec; 551(1-3):10-8. PubMed ID: 17027743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irreversible binding kinetics of neuropeptide Y ligands to Y2 but not to Y1 and Y5 receptors.
    Dautzenberg FM; Neysari S
    Pharmacology; 2005 Dec; 75(1):21-9. PubMed ID: 15908753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Labeling of neuropeptide Y receptors in SK-N-MC cells using the novel, nonpeptide Y1 receptor-selective antagonist [3H]BIBP3226.
    Entzeroth M; Braunger H; Eberlein W; Engel W; Rudolf K; Wienen W; Wieland HA; Willim KD; Doods HN
    Eur J Pharmacol; 1995 May; 278(3):239-42. PubMed ID: 7589160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural basis of ligand binding modes at the neuropeptide Y Y
    Yang Z; Han S; Keller M; Kaiser A; Bender BJ; Bosse M; Burkert K; Kögler LM; Wifling D; Bernhardt G; Plank N; Littmann T; Schmidt P; Yi C; Li B; Ye S; Zhang R; Xu B; Larhammar D; Stevens RC; Huster D; Meiler J; Zhao Q; Beck-Sickinger AG; Buschauer A; Wu B
    Nature; 2018 Apr; 556(7702):520-524. PubMed ID: 29670288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and characterization of pseudoirreversible nonpeptide antagonists of the neuropeptide Y Y5 receptor and development of a novel Y5-selective radioligand.
    Mullins D; Adham N; Hesk D; Wu Y; Kelly J; Huang Y; Guzzi M; Zhang X; McCombie S; Stamford A; Parker E
    Eur J Pharmacol; 2008 Dec; 601(1-3):1-7. PubMed ID: 18976648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of neuropeptide Y(2) receptors and suppression of NPY's anti-epileptic actions in the rat hippocampal slice by BIIE0246.
    El Bahh B; Cao JQ; Beck-Sickinger AG; Colmers WF
    Br J Pharmacol; 2002 Jun; 136(4):502-9. PubMed ID: 12055128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationships of neuropeptide Y Y1 receptor antagonists related to BIBP 3226.
    Aiglstorfer I; Hendrich I; Moser C; Bernhardt G; Dove S; Buschauer A
    Bioorg Med Chem Lett; 2000 Jul; 10(14):1597-600. PubMed ID: 10915060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability.
    Kanatani A; Kanno T; Ishihara A; Hata M; Sakuraba A; Tanaka T; Tsuchiya Y; Mase T; Fukuroda T; Fukami T; Ihara M
    Biochem Biophys Res Commun; 1999 Dec; 266(1):88-91. PubMed ID: 10581170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.